{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T17:45:24Z","timestamp":1757699124361,"version":"3.37.3"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T00:00:00Z","timestamp":1705017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>A 53-year-old man with adult-onset Still\u2019s disease developed severe streptococcal toxic shock syndrome (STSS) due to Streptococcus dysgalactiae subsp. equisimilis (SDSE), following retroperitoneal panniculitis. He was receiving tocilizumab (TCZ), an interleukin-6 receptor inhibitor. The modifying effect of TCZ on the immune response and the pathophysiology of SDSE infection may have led to retroperitoneal panniculitis and atypical STSS with delayed shock and flare of soft tissue inflammation.<\/jats:p>","DOI":"10.1093\/mrcr\/rxae001","type":"journal-article","created":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T06:03:44Z","timestamp":1705125824000},"page":"255-258","source":"Crossref","is-referenced-by-count":4,"title":["Streptococcal toxic shock syndrome due to <i>Streptococcus dysgalactiae<\/i> subsp. <i>equisimilis from<\/i> retroperitoneal panniculitis during the treatment with anti-IL-6 receptor antibody: A case report"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2671-1690","authenticated-orcid":false,"given":"Sho","family":"Fujimoto","sequence":"first","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology\/Infectious Disease, Kyushu University Hospital , Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5803-230X","authenticated-orcid":false,"given":"Yoshihiro","family":"Eriguchi","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology\/Infectious Disease, Kyushu University Hospital , Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rinto","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology\/Infectious Disease, Kyushu University Hospital , Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sota","family":"Kamikawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology\/Infectious Disease, Kyushu University Hospital , Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Yonekawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology\/Infectious Disease, Kyushu University Hospital , Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Miyake","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology\/Infectious Disease, Kyushu University Hospital , Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Ono","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology\/Infectious Disease, Kyushu University Hospital , Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0914-9066","authenticated-orcid":false,"given":"Hiroaki","family":"Niiro","sequence":"additional","affiliation":[{"name":"Department of Medical Education, Faculty of Medical Sciences, Kyushu University Graduate School of Medical Sciences , Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,1,12]]},"reference":[{"key":"2024070814410400000_R1","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1046\/j.1469-0691.2002.00387.x","article-title":"Streptococcal toxic shock syndrome","volume":"8","author":"Stevens","year":"2002","journal-title":"Clin Microbiol Infect"},{"key":"2024070814410400000_R2","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1017\/S0950268814001265","article-title":"Increased prevalence of group A streptococcus isolates in streptococcal toxic shock syndrome cases in Japan from 2010 to 2012","volume":"143","author":"Ikebe","year":"2015","journal-title":"Epidemiol Infect"},{"key":"2024070814410400000_R3","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1002\/art.39761","article-title":"Risk of gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologic treatments","volume":"68","author":"Xie","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2024070814410400000_R4","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/rheumatology\/keab438","article-title":"Risk of diverticulitis and gastrointestinal perforation in rheumatoid arthritis treated with tocilizumab compared to rituximab or abatacept","volume":"61","author":"Rempenault","year":"2022","journal-title":"Rheumatology"},{"key":"2024070814410400000_R5","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1136\/annrheumdis-2016-209773","article-title":"Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs","volume":"76","author":"Strangfeld","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2024070814410400000_R6","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1086\/605085","article-title":"Human infections due to Streptococcus dysgalactiae subspecies equisimilis","volume":"49","author":"Brandt","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2024070814410400000_R7","doi-asserted-by":"crossref","first-page":"135","DOI":"10.14740\/jmc3902","article-title":"Tocilizumab-associated small bowel perforation in a young patient with rheumatoid arthritis: a lesson to remember during COVID-19 pandemic","volume":"13","author":"Saad","year":"2022","journal-title":"J Med Cases"},{"key":"2024070814410400000_R8","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s40264-018-0639-1","article-title":"Gastrointestinal perforations with biologics in patients with rheumatoid arthritis: implications for clinicians","volume":"41","author":"Jagpal","year":"2018","journal-title":"Drug Saf"},{"key":"2024070814410400000_R9","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1469-0691.2008.02672.x","article-title":"Clinical presentations and epidemiology of \u03b2-haemolytic streptococcal bacteraemia: a population-based study","volume":"15","author":"Rantala","year":"2009","journal-title":"Clin Microbiol Infect"},{"key":"2024070814410400000_R10","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1086\/513947","article-title":"Aerobic and anaerobic microbiology of retroperitoneal abscesses","volume":"26","author":"Brook","year":"1998","journal-title":"Clin Infect Dis"},{"key":"2024070814410400000_R11","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S0022-3468(86)80112-9","article-title":"Streptocococcal sepsis presenting as acute abdomen in a child with transient hypogammaglobulinemia of infancy","volume":"21","author":"Kosnik","year":"1986","journal-title":"J Pediatr Surg"},{"key":"2024070814410400000_R12","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/BF01967085","article-title":"Silent spontaneous retroperitoneal abscess caused by M-type 18 Streptococcus pyogenes","volume":"11","author":"Llibre","year":"1992","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2024070814410400000_R13","doi-asserted-by":"crossref","DOI":"10.1186\/s13613-018-0438-y","article-title":"Streptococcal toxic shock syndrome in the intensive care unit","volume":"8","author":"Schmitz","year":"2018","journal-title":"Ann Intensive Care"},{"key":"2024070814410400000_R14","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1469-0691.2005.01169.x","article-title":"Invasive group A, B, C and G streptococcal infections in Denmark 1999\u20132002: epidemiological and clinical aspects","volume":"11","author":"Ekelund","year":"2005","journal-title":"Clin Microbiol Infect"},{"key":"2024070814410400000_R15","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1128\/JCM.00422-08","article-title":"Epidemiology of severe Streptococcus pyogenes disease in Europe","volume":"46","author":"Lamagni","year":"2008","journal-title":"J Clin Microbiol"},{"key":"2024070814410400000_R16","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/rheumatology\/ker336","article-title":"Necrotizing fasciitis in a rheumatoid arthritis patient treated with tocilizumab","volume":"51","author":"Van De Sande","year":"2012","journal-title":"Rheumatology"},{"key":"2024070814410400000_R17","first-page":"275","article-title":"Fatal necrotizing fasciitis in a patient with rheumatoid arthritis receiving tocilizumab","volume":"32","author":"Ogawa","year":"2020","journal-title":"Clin Rheumatol Rel Res"},{"key":"2024070814410400000_R18","doi-asserted-by":"crossref","first-page":"370","DOI":"10.2340\/00015555-1952","article-title":"Development of necrotising fasciitis in a patient treated for rheumatoid arthritis with tocilizumab","volume":"95","author":"Hashimoto","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"2024070814410400000_R19","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3109\/s10165-011-0505-9","article-title":"Necrotizing fasciitis in a patient with rheumatoid arthritis treated with tocilizumab","volume":"22","author":"Yoshida","year":"2012","journal-title":"Mod Rheumatol"},{"key":"2024070814410400000_R20","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1684\/ejd.2022.4249","article-title":"Necrotizing fasciitis with slow progression in a patient with rheumatoid arthritis receiving tocilizumab","volume":"32","author":"Goto","year":"2022","journal-title":"Eur J Dermatol"},{"key":"2024070814410400000_R21","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.reuma.2016.10.008","article-title":"Necrotizing fasciitis in a patient receiving tocilizumab for rheumatoid arthritis \u2022 Case report","volume":"14","author":"Rosa-Gon\u00e7alves","year":"2018","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"2024070814410400000_R22","first-page":"951","article-title":"Streptococcal lung abscesses from a dental focus following tocilizumab: a case report","volume":"30","author":"de Kruif","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"2024070814410400000_R23","article-title":"The absence of typical pneumonia symptoms in a patient with rheumatoid arthritis during tocilizumab and steroid treatment","volume":"2012","author":"Yanagawa","year":"2012","journal-title":"BMJ Case Rep"},{"key":"2024070814410400000_R24","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3109\/s10165-008-0111-7","article-title":"Masked early symptoms of pneumonia in patients with rheumatoid arthritis during tocilizumab treatment: a report of two cases","volume":"19","author":"Fujiwara","year":"2009","journal-title":"Mod Rheumatol"},{"key":"2024070814410400000_R25","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.burns.2022.08.018","article-title":"Th1\/Th2 cytokine levels: a potential diagnostic tool for patients with necrotizing fasciitis","volume":"49","author":"Ling","year":"2023","journal-title":"Burns"},{"key":"2024070814410400000_R26","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jiac.2019.01.006","article-title":"Streptococcal toxic shock syndrome caused by \u03b2-hemolytic streptococci: clinical features and cytokine and chemokine analyses of 15 cases","volume":"25","author":"Yoshizawa","year":"2019","journal-title":"J Infect Chemother"},{"key":"2024070814410400000_R27","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1128\/JCM.41.2.613-618.2003","article-title":"Analysis of a viridans group strain reveals a case of bacteremia due to lancefield group g alpha-hemolytic streptococcus dysgalactiae subsp. equisimilis in a patient with pyomyositis and reactive arthritis","volume":"41","author":"Woo","year":"2003","journal-title":"J Clin Microbiol"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxae001\/56532299\/rxae001.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/8\/2\/255\/58470469\/rxae001.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/8\/2\/255\/58470469\/rxae001.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T14:43:21Z","timestamp":1720449801000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/8\/2\/255\/7523753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,12]]},"references-count":27,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,1,12]]},"published-print":{"date-parts":[[2024,7,8]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxae001","relation":{},"ISSN":["2472-5625"],"issn-type":[{"type":"electronic","value":"2472-5625"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2024,1,12]]}}}